がん遺伝子治療の市場規模、シェア、成長分析：タイプ別、治療法別、製品別、最終用途別、地域別 - 産業予測 2025～2032年

がん遺伝子治療の世界市場規模は、2023年に35億米ドルと評価され、2024年の42億5,000万米ドルから2032年には200億5,000万米ドルに成長し、予測期間（2025-2032年）のCAGRは21.4％で成長する見通しです。

世界のがん罹患率の上昇が、がん遺伝子治療市場の成長に大きな影響を与えています。主な促進要因としては、革新的ながん治療に対する需要の増加、遺伝子工学技術の発展、新規治療法の開発に向けた多額の投資などが挙げられます。企業は、進行中の腫瘍学研究や生存率向上を目的とした個別化治療オプションへの要望を背景に、新たな遺伝子治療の創出を優先しています。さらに、がん患者に対する政府の支援は、治療提供者にさらなる機会をもたらしています。しかし、治療費の高さ、副作用の可能性、製造上のハードルといった課題は、市場の長期的開発の可能性を制限する可能性があります。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次と一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析

がん遺伝子治療市場規模：タイプ別& CAGR（2025-2032）

• 市場概要
• 生体外
• 生体内

がん遺伝子治療市場規模：治療法別& CAGR（2025-2032）

• 市場概要
• 腫瘍溶解性ウイルス療法
• 遺伝子誘導免疫療法
• 遺伝子導入

がん遺伝子治療市場規模：製品別& CAGR（2025-2032）

• 市場概要
• ウイルスベクター
  • アデノウイルス
  • レンチウイルス
  • レトロウイルス
  • アデノ随伴ウイルス
  • 単純ヘルペスウイルス
  • ワクシニアウイルス
  • その他のウイルスベクター
• 非ウイルスベクター
• その他の製品

がん遺伝子治療市場規模：最終用途別& CAGR（2025-2032）

• 市場概要
• バイオ医薬品企業
• 調査機関
• その他の最終用途

がん遺伝子治療市場規模：地域別& CAGR（2025-2032）

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 最近の市場動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 企業の詳細
  • 製品ポートフォリオ分析
  • 企業のセグメント別シェア分析
  • 収益の前年比比較（2022-2024）

主要企業プロファイル

• Novartis AG（Switzerland）
• Gilead Sciences, Inc.（USA）
• Bristol Myers Squibb Company（USA）
• CRISPR Therapeutics（Switzerland）
• Amgen Inc.（USA）
• Merck KGaA（Germany）
• Intellia Therapeutics, Inc.（USA）
• Adaptimmune Therapeutics（UK）
• Autolus Therapeutics（UK）
• Sangamo Therapeutics, Inc.（USA）
• Vertex Pharmaceuticals（USA）
• Abeona Therapeutics Inc.（USA）
• Johnson & Johnson（USA）
• Pfizer Inc.（USA）
• AstraZeneca（UK）
• Takeda Pharmaceutical Company Limited（Japan）

結論と提言

Global Cancer Gene Therapy Market size was valued at USD 3.5 billion in 2023 and is poised to grow from USD 4.25 billion in 2024 to USD 20.05 billion by 2032, growing at a CAGR of 21.4% during the forecast period (2025-2032).

The rising global incidence of cancer is significantly influencing the growth of the cancer gene therapy market. Key drivers include an increasing demand for innovative cancer treatments, advancements in genetic engineering technologies, and substantial investments directed towards the development of novel therapies. Companies are prioritizing the creation of new gene therapies fueled by ongoing research in oncology and the desire for personalized treatment options, which aim to enhance survival rates. Moreover, government support for cancer patients presents additional opportunities for therapy providers. However, challenges such as the high cost of treatments, the potential for adverse effects, and manufacturing hurdles could limit the market's long-term development potential.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cancer Gene Therapy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Cancer Gene Therapy Market Segments Analysis

Global Cancer Gene Therapy Market is segmented by Type, Therapy, Product, End Use and region. Based on Type, the market is segmented into Ex-Vivo and In-Vivo. Based on Therapy, the market is segmented into Oncolytic Virotherapy, Gene-Induced Immunotherapy and Gene Transfer. Based on Product, the market is segmented into Viral Vectors, Non-Viral Vectors and Other Products. Based on End Use, the market is segmented into Biopharma Companies, Research Institutes and Other End-Users. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Cancer Gene Therapy Market

The Global Cancer Gene Therapy market is significantly propelled by advancements in genetic engineering and genome mapping technologies, which have seen substantial investments in gene research initiatives. These breakthroughs in genetics are increasingly converging with oncology research, leading to the development of innovative cancer gene therapies. This integration not only enhances treatment options but also stimulates market expansion, reflecting the growing importance of personalized medicine in addressing complex cancer challenges. As these technologies evolve, they are set to further accelerate the growth of the cancer gene therapy sector, ultimately striving to improve patient outcomes and revolutionize cancer treatment methodologies.

Restraints in the Global Cancer Gene Therapy Market

The Global Cancer Gene Therapy market faces significant restraints primarily due to the high costs associated with these advanced treatments. The expenses incurred from sophisticated equipment and thorough research and development processes make gene therapy inaccessible for many cancer patients. These financial barriers hinder the widespread adoption of cancer gene therapy, as not all patients can afford the treatment. Consequently, the high pricing remains a critical factor that limits the potential growth of the market, as cost-effective alternatives are often sought in the pursuit of effective cancer therapies. This economic limitation poses challenges for both patients and healthcare providers in accessing these innovative solutions.

Market Trends of the Global Cancer Gene Therapy Market

The Global Cancer Gene Therapy market is witnessing a significant trend toward the growing demand for combination therapies, driven by an increasing number of cancer patients seeking enhanced survival rates and improved treatment outcomes. This shift presents a strategic opportunity for cancer gene therapy providers to innovate and expand their offerings by developing novel combination therapies that synergistically leverage the effects of various treatment modalities, such as targeted therapies, immunotherapies, and traditional chemotherapies. By prioritizing research and collaboration, these providers can not only address the evolving needs of patients but also maximize their market potential and reinforce their competitive edge in the long-term landscape of oncology.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Cancer Gene Therapy Market Size by Type & CAGR (2025-2032)

• Market Overview
• Ex-Vivo
• In-Vivo

Global Cancer Gene Therapy Market Size by Therapy & CAGR (2025-2032)

• Market Overview
• Oncolytic Virotherapy
• Gene-Induced Immunotherapy
• Gene Transfer

Global Cancer Gene Therapy Market Size by Product & CAGR (2025-2032)

• Market Overview
• Viral Vectors
  • Adenoviruses
  • Lentiviruses
  • Retrovirus
  • Adeno Associated Virus
  • Herpes Simplex Virus
  • Vaccinia Virus
  • Other Viral Vectors
• Non-Viral Vectors
• Other Products

Global Cancer Gene Therapy Market Size by End Use & CAGR (2025-2032)

• Market Overview
• Biopharma Companies
• Research Institutes
• Other End-Users

Global Cancer Gene Therapy Market Size & CAGR (2025-2032)

• North America (Type, Therapy, Product, End Use)
  • US
  • Canada
• Europe (Type, Therapy, Product, End Use)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Therapy, Product, End Use)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Therapy, Product, End Use)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Therapy, Product, End Use)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CRISPR Therapeutics (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Intellia Therapeutics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Adaptimmune Therapeutics (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Autolus Therapeutics (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sangamo Therapeutics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vertex Pharmaceuticals (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abeona Therapeutics Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations